Autoimmune hemolytic anemia: classification and therapeutic approaches

References

• Sokol RJ, Booker DJ, Stamps R. The pathology of autoimmune haemolytic anaemia. J. Clin. Pathol.45(12), 1047–1052 (1992).
   PubMed Web of Science ®Google Scholar
• Bottiger LE, Westerholm B. Acquired haemolytic anaemia. I. Incidence and aetiology. Acta Med. Scand.193(3), 223–226 (1973).
   PubMedGoogle Scholar
• Ravetch JV, Kinet JP. Fc receptors. Annu. Rev. Immunol.9, 457–492 (1991).
   PubMed Web of Science ®Google Scholar
• Ehlenberger AG, Nussenzweig V. The role of membrane receptors for C3b and C3d in phagocytosis. J. Exp. Med.145(2), 357–371 (1977).
   PubMed Web of Science ®Google Scholar
• Toriani-Terenzi C, Fagiolo E. IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia. Ann. NY Acad. Sci.1051, 29–44 (2005).
   PubMed Web of Science ®Google Scholar
• Perry FE, Barker RN, Mazza G et al. Autoreactive T cell specificity in autoimmune hemolytic anemia of the NZB mouse. Eur. J. Immunol.26(1), 136–141 (1996).
   PubMed Web of Science ®Google Scholar
• Fagiolo E, Toriani-Terenzi C. Th1 and Th2 cytokine modulation by IL-10/IL-12 imbalance in autoimmune haemolytic anaemia (AIHA). Autoimmunity35(1), 39–44 (2002).
   PubMed Web of Science ®Google Scholar
• Mqadmi A, Zheng X, Yazdanbakhsh K. CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood105(9), 3746–3748 (2005).
   PubMed Web of Science ®Google Scholar
• Ward FJ, Hall AM, Cairns LS et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood111(2), 680–687 (2008).
   PubMed Web of Science ®Google Scholar
• Dacie JV. Autoimmune hemolytic anemia. Arch. Intern. Med.135, 1293–300 (1975).
   PubMedGoogle Scholar
• Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am. J. Hematol.69(4), 258–271 (2002).
   PubMed Web of Science ®Google Scholar
• Michel M. Warm autoimmune hemolytic anemias and Evans syndrome in adults. Rev. Med. Interne29(2), 105–114 (2008).
   PubMed Web of Science ®Google Scholar
• Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev.22(1), 17–31 (2008).
   PubMed Web of Science ®Google Scholar
• Bell CA, Zwicker H, Sacks HJ. Autoimmune hemolytic anemia: routine serologic evaluation in a general hospital population. Am. J. Clin. Pathol.60(6), 903–911 (1973).
   PubMed Web of Science ®Google Scholar
• Dausset J, Colombani J. The serology and the prognosis of 128 cases of autoimmune hemolytic anemia. Blood14, 1280–1301 (1959).
   PubMed Web of Science ®Google Scholar
• Evans RS, Weiser RS. The serology of autoimmune hemolytic disease; observations on forty-one patients. AMA Arch. Intern. Med.100(3), 371–399 (1957).
   PubMedGoogle Scholar
• Genty I, Michel M, Hermine O et al. Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases. Rev. Med. Interne23(11), 901–909 (2002).
   PubMed Web of Science ®Google Scholar
• Gomard-Mennesson E, Ruivard M, Koenig M et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus15(4), 223–231 (2006).
   PubMed Web of Science ®Google Scholar
• Seve P, Bourdillon L, Sarrot-Reynauld F et al. Autoimmune hemolytic anemia and common variable immunodeficiency: a case–control study of 18 patients. Medicine (Baltimore)87(3), 177–184 (2008).
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Langholm R et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica91(4), 460–466 (2006).
   PubMed Web of Science ®Google Scholar
• Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J. Pediatr.70(6), 891–899 (1967).
   PubMed Web of Science ®Google Scholar
• Sneller MC, Wang J, Dale JK et al. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood89(4), 1341–1348 (1997).
   PubMed Web of Science ®Google Scholar
• Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale–Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med.335(22), 1643–1649 (1996).
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Le Deist F, Hivroz C et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science268(5215), 1347–1349 (1995).
   PubMed Web of Science ®Google Scholar
• Chun HJ, Zheng L, Ahmad M et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature419(6905), 395–399 (2002).
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng L, Lobito A et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell98(1), 47–58 (1999).
   PubMed Web of Science ®Google Scholar
• Young PP, Uzieblo A, Trulock E, Lublin DM, Goodnough LT. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion44(1), 67–72 (2004).
   PubMed Web of Science ®Google Scholar
• Garratty G. Autoantibodies induced by blood transfusion. Transfusion44(1), 5–9 (2004).
   PubMed Web of Science ®Google Scholar
• Sanz J, Arriaga F, Montesinos P et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant.39(9), 555–561 (2007).
   PubMed Web of Science ®Google Scholar
• Ramsey G. Red cell antibodies arising from solid organ transplants. Transfusion31(1), 76–86 (1991).
   PubMed Web of Science ®Google Scholar
• Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin. Hematol.42(3), 137–144 (2005).
   PubMed Web of Science ®Google Scholar
• Arndt PA, Garratty G. Cross-reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other: cephalosporins and penicillin. Am. J. Clin. Pathol.118(2), 256–262 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson ST, Fueger JT, Gottschall JL. One center’s experience: the serology and drugs associated with drug-induced immune hemolytic anemia – a new paradigm. Transfusion47(4), 697–702 (2007).
   PubMed Web of Science ®Google Scholar
• Myint H, Copplestone JA, Orchard J et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br. J. Haematol.91(2), 341–344 (1995).
   PubMed Web of Science ®Google Scholar
• Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J. Clin. Oncol.16(5), 1885–1889 (1998).
   PubMed Web of Science ®Google Scholar
• Fleischman RA, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am. J. Hematol.48(4), 293 (1995).
   PubMed Web of Science ®Google Scholar
• Lauchli S, Widmer L, Lautenschlager S. Cold agglutinin disease – the importance of cutaneous signs. Dermatology202(4), 356–358 (2001).
   PubMed Web of Science ®Google Scholar
• Philippe P. Autoimmune hemolytic anemia: diagnosis and management. Presse Med.36(12 Pt 3), 1959–1969 (2007).
   PubMed Web of Science ®Google Scholar
• Owen JA, de Gruchy GC, Smith H. Serum haptoglobins in haemolytic states. J. Clin. Pathol.13(6), 478–482 (1960).
   PubMed Web of Science ®Google Scholar
• Freedman J. The significance of complement on the red cell surface. Transfus. Med. Rev.1(1), 58–70 (1987).
   PubMedGoogle Scholar
• Garratty G. Immune hemolytic anemia associated with negative routine serology. Semin. Hematol.42(3), 156–164 (2005).
   PubMed Web of Science ®Google Scholar
• Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiology207(1), 5–11 (2003).
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Ngo M, Iqbal S, Espina B, Liebman HA. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br. J. Haematol.118(4), 1166–1169 (2002).
   PubMed Web of Science ®Google Scholar
• Berentsen S, Beiske K, Tjonnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology, 12(5), 361–370 (2007).
   PubMed Web of Science ®Google Scholar
• Petz LD. Treatment of autoimmune hemolytic anemias. Curr. Opin. Hematol.8(6), 411–416 (2001).
   PubMed Web of Science ®Google Scholar
• Allgood JW, Chaplin H Jr. Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. Am. J. Med.43(2), 254–273 (1967).
   PubMed Web of Science ®Google Scholar
• Murphy S, LoBuglio AF. Drug therapy of autoimmune hemolytic anemia. Semin. Hematol.13(4), 323–334 (1976).
   PubMed Web of Science ®Google Scholar
• Bowdler AJ. The role of the spleen and splenectomy in autoimmune hemolytic disease. Semin. Hematol.13(4), 335–348 (1976).
   PubMed Web of Science ®Google Scholar
• Christensen BE. The pattern of erythrocyte sequestration in immunohaemolysis. Effects of prednisone treatment and splenectomy. Scand. J. Haematol.10(2), 120–129 (1973).
   PubMedGoogle Scholar
• Schwartz SI, Bernard RP, Adams JT, Bauman AW. Splenectomy for hematologic disorders. Arch. Surg.101(2), 338–347 (1970).
   PubMed Web of Science ®Google Scholar
• Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J. Infect.43(3), 182–186 (2001).
   PubMed Web of Science ®Google Scholar
• Newland A, Provan D, Myint S. Preventing severe infection after splenectomy. BMJ331(7514), 417–418 (2005).
   PubMed Web of Science ®Google Scholar
• Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. BMJ312(7028), 430–434 (1996).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood90(6), 2188–2195 (1997).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.346(4), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis.61(10), 883–888 (2002).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum.46(10), 2673–2677 (2002).
   PubMed Web of Science ®Google Scholar
• Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood101(10), 3827–3834 (2003).
   PubMed Web of Science ®Google Scholar
• Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood98(4), 952–957 (2001).
   PubMed Web of Science ®Google Scholar
• Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br. J. Haematol.141(2), 149–169 (2008).
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Sperotto A et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk. Lymphoma44(11), 1951–1955 (2003).
   PubMed Web of Science ®Google Scholar
• Quartier P, Brethon B, Philippet P et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet358(9292), 1511–1513 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta N, Kavuru S, Patel D et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia16(10), 2092–2095 (2002).
   PubMed Web of Science ®Google Scholar
• Trape G, Fianchi L, Lai M et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica88(2), 223–225 (2003).
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin. Proc.78(11), 1340–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica90(9), 1273–1274 (2005).
   PubMed Web of Science ®Google Scholar
• D’Arena G, Laurenti L, Capalbo S et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am. J. Hematol.81(8), 598–602 (2006).
   PubMed Web of Science ®Google Scholar
• D’Arena G, Califano C, Annunziata M et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur. J. Haematol.79(1), 53–58 (2007).
   PubMed Web of Science ®Google Scholar
• Zecca M, Nobili B, Ramenghi U et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood101(10), 3857–3861 (2003).
   PubMed Web of Science ®Google Scholar
• Lindholm C, Borjesson-Asp K, Zendjanchi K et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J. Rheumatol.35(5), 826–833 (2008).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Thrasher AJ, Jones AM, Davies EG, Cale CM. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br. J. Haematol.138(1), 94–96 (2007).
   PubMed Web of Science ®Google Scholar
• King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin. Hematol.42(3), 131–136 (2005).
   PubMed Web of Science ®Google Scholar
• Moyo VM, Smith D, Brodsky I et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood100(2), 704–706 (2002).
   PubMed Web of Science ®Google Scholar
• Emilia G, Messora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br. J. Haematol.93(2), 341–344 (1996).
   PubMed Web of Science ®Google Scholar
• Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br. J. Haematol.117(3), 712–715 (2002).
   PubMed Web of Science ®Google Scholar
• Kotb R, Pinganaud C, Trichet C et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur. J. Haematol.75(1), 60–64 (2005).
   PubMed Web of Science ®Google Scholar
• Zimmer-Molsberger B, Knauf W, Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anemia. Lancet350(9083), 1003–1004 (1997).
   PubMed Web of Science ®Google Scholar
• Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus12(8), 633–635 (2003).
   PubMed Web of Science ®Google Scholar
• Rao VK, Dugan F, Dale JK et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br. J. Haematol.129(4), 534–538 (2005).
   PubMed Web of Science ®Google Scholar
• Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol.84(3), 122–129 (1990).
   PubMed Web of Science ®Google Scholar
• Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br. J. Haematol.83(2), 343–345 (1993).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Seve P, Broussolle C, Renaudier P, Ducerf C. Danazol-induced hepatocellular carcinoma. QJM96(4), 317–318 (2003).
   PubMed Web of Science ®Google Scholar
• Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am. J. Hematol.44(4), 237–242 (1993).
   PubMed Web of Science ®Google Scholar
• McLeod BC. Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias. Curr. Opin. Hematol.14(6), 647–654 (2007).
   PubMed Web of Science ®Google Scholar
• Ruivard M, Tournilhac O, Montel S et al. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: a retrospective case–control study. J. Clin. Apher.21(3), 202–206 (2006).
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Biology and management of acquired severe aplastic anemia. Curr. Opin. Oncol.10(2), 95–99 (1998).
   PubMedGoogle Scholar
• Passweg JR, Rabusin M, Musso M et al. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br. J. Haematol.125(6), 749–755 (2004).
   PubMed Web of Science ®Google Scholar
• Willis F, Marsh JC, Bevan DH et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br. J. Haematol.114(4), 891–898 (2001).
   PubMed Web of Science ®Google Scholar
• Cheung WW, Hwang GY, Tse E, Kwong YL. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica91(5 Suppl.), ECR13 (2006).
   PubMedGoogle Scholar
• Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia21(3), 511–514 (2007).
   PubMed Web of Science ®Google Scholar
• King KE. Review: pharmacologic treatment of warm autoimmune hemolytic anemia. Immunohematology23(3), 120–129 (2007).
   PubMedGoogle Scholar
• Drouillard DD. Transfusion therapy for autoimmune hemolytic anemia patients: a laboratory perspective. Clin. Lab. Sci.21(1), 7–11 (2008).
   PubMedGoogle Scholar
• Branch DR, Petz LD. Detecting alloantibodies in patients with autoantibodies. Transfusion39(1), 6–10 (1999).
   PubMed Web of Science ®Google Scholar
• Plapp FV, Beck ML. Transfusion support in the management of immune haemolytic disorders. Clin. Haematol.13(1), 167–183 (1984).
   PubMedGoogle Scholar
• Sallah S, Wan JY, Hanrahan LR. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. Clin. Cancer Res.7(4), 791–794 (2001).
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Pfeiffer RM, Engels EA et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin’s lymphoma. Arthritis Rheum.58(3), 657–666 (2008).
   PubMed Web of Science ®Google Scholar
• Ekstrom Smedby K, Vajdic CM, Falster M et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood111(8), 4029–4038 (2008).
   PubMed Web of Science ®Google Scholar
• Hendrick AM. Auto-immune haemolytic anaemia – a high-risk disorder for thromboembolism? Hematology8(1), 53–56 (2003).
   PubMedGoogle Scholar
• Wolach B, Heddle N, Barr RD et al. Transient Donath–Landsteiner haemolytic anaemia. Br. J. Haematol.48(3), 425–434 (1981).
   PubMed Web of Science ®Google Scholar
• Berentsen S, Bo K, Shammas FV, Myking AO, Ulvestad E. Chronic cold agglutinin disease of the “idiopathic” type is a premalignant or low-grade malignant lymphoproliferative disease. Apmis105(5), 354–362 (1997).
   PubMed Web of Science ®Google Scholar
• Petz LD. Cold antibody autoimmune hemolytic anemias. Blood Rev.22(1), 1–15 (2008).
   PubMed Web of Science ®Google Scholar
• Evans RS, Bingham M, Turner E. Autoimmune hemolytic disease: observations of serological reactions and disease activity. Ann. NY Acad. Sci.124(2), 422–440 (1965).
   PubMed Web of Science ®Google Scholar
• Schreiber AD, Herskovitz BS, Goldwein M. Low-titer cold-hemagglutinin disease. Mechanism of hemolysis and response to corticosteroids. N. Engl. J. Med.296(26), 1490–1494 (1977).
   PubMed Web of Science ®Google Scholar
• Nanan R, Scheurlen W, Gerlich M, Huppertz HI. Severe low-titer cold-hemagglutinin disease responsive to steroid pulse therapy. Ann. Hematol.71(2), 101–102 (1995).
   PubMed Web of Science ®Google Scholar
• Silberstein LE, Berkman EM, Schreiber AD. Cold hemagglutinin disease associated with IgG cold-reactive antibody. Ann. Intern. Med.106(2), 238–242 (1987).
   PubMed Web of Science ®Google Scholar
• Hippe E, Jensen KB, Olesen H, Lind K, Thomsen PE. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood35(1), 68–72 (1970).
   PubMed Web of Science ®Google Scholar
• Jacobs A. Cold agglutinin hemolysis responding to fludarabine therapy. Am. J. Hematol.53(4), 279–280 (1996).
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood103(8), 2925–2928 (2004).
   PubMed Web of Science ®Google Scholar
• Schollkopf C, Kjeldsen L, Bjerrum OW et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk. Lymphoma47(2), 253–260 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connor BM, Clifford JS, Lawrence WD, Logue GL. α-interferon for severe cold agglutinin disease. Ann. Intern. Med.111(3), 255–256 (1989).
   PubMed Web of Science ®Google Scholar
• Hillen HF, Bakker SJ. Failure of interferon-α-2b therapy in chronic cold agglutinin disease. Eur. J. Haematol.53(4), 242–243 (1994).
   PubMed Web of Science ®Google Scholar
• McLeod BC, Strauss RG, Ciavarella D et al. Management of hematological disorders and cancer. J. Clin. Apher.8(4), 211–230 (1993).
   PubMedGoogle Scholar
• Besa EC. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. Am. J. Med.84(4), 691–698 (1988).
   PubMed Web of Science ®Google Scholar
• Vassou A, Alymara V, Chaidos A, Bourantas KL. Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease. Int. J. Hematol.81(5), 421–423 (2005).
   PubMed Web of Science ®Google Scholar
• Weber DM, Dimopoulos MA, Delasalle K et al. 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom’s macroglobulinemia. Semin. Oncol.30(2), 243–247 (2003).
   PubMed Web of Science ®Google Scholar
• Berentsen S, Tjonnfjord GE. Rituximab and fludarabine combination therapy for chronic cold agglutinin disease. Haematologica91(Suppl. 1), 11 (2006).
   PubMed Web of Science ®Google Scholar
• Hill A, Hillmen P, Richards SJ et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood106(7), 2559–2565 (2005).
   PubMed Web of Science ®Google Scholar
• Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med.350(6), 552–559 (2004).
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med.355(12), 1233–1243 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenfield RE, Jagathambal K. Transfusion therapy for autoimmune hemolytic anemia. Semin. Hematol.13(4), 311–321 (1976).
   PubMed Web of Science ®Google Scholar
• Schubothe H. The cold hemagglutinin disease. Semin. Hematol.3(1), 27–47 (1966).
   PubMedGoogle Scholar
• Garcia VP, de Quiros JF, Caminal L. Autoimmune hemolytic anemia associated with eosinophilic fasciitis. J. Rheumatol.25(9), 1864–1865 (1998).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, García-Carrasco M, López-Medrano F et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine82(2), 87–96 (2003).
   PubMed Web of Science ®Google Scholar
• Morell S, Lambert M, Queyrel V et al. adenitis and Evans’ syndrome. Lupus15(2), 114–115 (2006).
   PubMed Web of Science ®Google Scholar
• Koduri PR, Singa P, Nikolinakos P. Autoimmune hemolytic anemia in patients infected with human immunodeficiency virus-1. Am. J. Hematol.70(2), 174–176 (2002).
   PubMed Web of Science ®Google Scholar